Advertisement
U.S. markets closed

Genfit S.A. (XUPB.MU)

Munich - Munich Delayed Price. Currency in EUR
3.32000.0000 (0.00%)
At close: 08:14AM CEST
Full screen
Add
Comparison
Indicators
Technicals
Corporate Events
Mountain
DrawTable View
Settings
AllAllFavoritesTextStatisticsTechnicalsFibonacciMarkingsLines
Loading interactive chart...
1D
Date Range
Interval:
1 min
  • GlobeNewswire

    GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents

    Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland); April 15, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced that it published in the April 15, 2024 French legal announcements bulletin n°46 (Bulletin des Annonces Légales Obligatoires) its convening notice that the Combined Shareholders Meeting will be held on May 22, 2024, at 1

  • GlobeNewswire

    GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F

    Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), April 5, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the filing of its 2023 Universal Registration Document with the Autorité des marchés financiers (AMF ; filing n° D.24-0246) and its Annual Report on Form 20-F for the year ended December 31, 2023 with the U.S. Securities

  • GlobeNewswire

    GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

    Cash and cash equivalents totaled €77.8 million as of December 31, 2023Revenues amounted to €28.6 million as of December 31, 2023 including a milestone payment of €13.3 millionTopline interim data for Phase 2 UNVEIL-IT® trial in ACLF expected in 2H24FDA PDUFA action date for elafibranor in PBC: June 10, 2024 Lille, France; Cambridge, MA; Zurich, Switzerland; April 4, 2024 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients wit